Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $21.57 Average Target Price from Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received an average rating of “Buy” from the eight research firms that are presently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $21.57.

Several research analysts have commented on CLBT shares. Craig Hallum raised their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 16th. Finally, Needham & Company LLC boosted their price target on Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $25.41 on Friday. Cellebrite DI has a one year low of $8.91 and a one year high of $26.30. The company’s 50 day moving average price is $22.21 and its 200 day moving average price is $18.73.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. During the same quarter last year, the firm posted $0.09 EPS. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. Equities analysts anticipate that Cellebrite DI will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Cellebrite DI

A number of hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in shares of Cellebrite DI by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock valued at $7,202,000 after buying an additional 75,092 shares during the last quarter. Telemark Asset Management LLC acquired a new stake in Cellebrite DI in the third quarter valued at $6,736,000. Two Sigma Advisers LP boosted its stake in Cellebrite DI by 9.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock valued at $22,584,000 after acquiring an additional 120,000 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in shares of Cellebrite DI by 65.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock worth $3,473,000 after purchasing an additional 62,320 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Cellebrite DI by 7.3% in the 3rd quarter. State Street Corp now owns 443,700 shares of the company’s stock valued at $7,472,000 after purchasing an additional 30,052 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.